Incorporating novel agents in the treatment of myelodysplastic syndromes.
about
Referrals for suspected hematologic malignancy: a survey of primary care physicians.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Epigenetic regulation in myelodysplastic syndromes: implications for therapy.A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.
P2860
Incorporating novel agents in the treatment of myelodysplastic syndromes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incorporating novel agents in the treatment of myelodysplastic syndromes.
@en
Incorporating novel agents in the treatment of myelodysplastic syndromes.
@nl
type
label
Incorporating novel agents in the treatment of myelodysplastic syndromes.
@en
Incorporating novel agents in the treatment of myelodysplastic syndromes.
@nl
prefLabel
Incorporating novel agents in the treatment of myelodysplastic syndromes.
@en
Incorporating novel agents in the treatment of myelodysplastic syndromes.
@nl
P2093
P1433
P1476
Incorporating novel agents in the treatment of myelodysplastic syndromes.
@en
P2093
Evangelos Terpos
Konstantinos Anargyrou
Maria K Angelopoulou
Theodoros P Vassilakopoulos
P356
10.1016/J.LEUKRES.2009.07.021
P577
2009-08-04T00:00:00Z